Inozyme Pharma Inc. (INZY) News

Inozyme Pharma Inc. (INZY): $2.57

-0.03 (-1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INZY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter INZY News Items

INZY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INZY News Highlights

  • For INZY, its 30 day story count is now at 2.
  • Over the past 20 days, the trend for INZY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • MSC are the most mentioned tickers in articles about INZY.

Latest INZY News From Around the Web

Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | September 26, 2022

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET. A replay of

Yahoo | September 6, 2022

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

Yahoo | August 24, 2022

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

Yahoo | August 23, 2022

bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

Yahoo | August 18, 2022

Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

Yahoo | August 17, 2022

Needham Sticks to Their Buy Rating for Inozyme Pharma (INZY)

Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma (INZY - Research Report) today and set a price target of $23.00. The company's shares opened today at $3.41.Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Lexicon Pharmaceuticals. According to TipRanks, Stringer has an average return of 5.3% and a 46.63% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inozyme Pharma with a $22.00 average price target, representing a 545.16% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.

Jason Carr on TipRanks | August 15, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Inozyme Pharma (INZY)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Inozyme Pharma (INZY - Research Report), with a price target of $20.00. The company's shares opened today at $3.41.White covers the Healthcare sector, focusing on stocks such as Clovis Oncology, G1 Therapeutics, and ChemoCentryx. According to TipRanks, White has an average return of -14.7% and a 32.96% success rate on recommended stocks. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $22.00, a 545.16% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $23.00 price target.

Jason Carr on TipRanks | August 15, 2022

Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - Secured flexible debt facility for up to $70 million - - Cash, cash equivalents and investments as of quarter end, together with first tranche of debt facility, funds cash flow requirements into the second quarter of 2024 – BOSTON, Aug. 15, 2022 (GLOBE NE

Yahoo | August 15, 2022

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Yahoo | August 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7767 seconds.